Cardiovascular Center of Sarasota

Sarasota, Florida 34239-3513

1 studies enrolling now · 31 studies all time

What they study most

Acute Coronary Syndrome, Angina Pectoris, Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Atrial Fibrillation, Cardiovascular Disease, Cardiovascular Diseases, Chronic Kidney Disease (CKD), Congestive Heart Failure, Coronary Artery Disease, Coronary Disease, Coronary Heart Disease (CHD)

Studies at this site

• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
• Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD — Running, not enrolling
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
• A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) — Completed
• International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) — Completed
• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function — Completed
• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment — Completed
• Firibastat in Treatment-resistant Hypertension — Completed
• GLORIA-AF Registry Program - Second and Third Phases — Completed
• A Study of LY2623091 in Participants With High Blood Pressure — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• A Phase III Study of Apixaban in Patients With Atrial Fibrillation — Completed
• Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina — Completed
• DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension — Completed
• DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension — Completed
• DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension — Stopped early
• DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension — Stopped early
• A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus — Completed
• EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan — Completed
• Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure. — Completed
• Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS) — Completed
• PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients — Status unconfirmed
• The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC — Completed
• A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack — Stopped early